HOUSE_OVERSIGHT_024022.jpg
2.3 MB
Extraction Summary
1
People
25
Organizations
0
Locations
2
Events
3
Relationships
3
Quotes
Document Information
Type:
Investment prospectus / private placement memorandum
File Size:
2.3 MB
Summary
This document is page 11 of a confidential presentation (likely an investment prospectus for 'NLV-III') detailing the history and senior team of New Leaf Ventures. It features a timeline of funds raised from 1993 to 2007 under Sprout and New Leaf brands, totaling billions in capital. The page highlights the biography of Managing Director Philippe Chambon, detailing his history with Sprout, Boston Consulting Group, and Sandoz Pharmaceutical, as well as his numerous board memberships in the healthcare and biotech sectors. The document bears a House Oversight Committee control number.
People (1)
| Name | Role | Context |
|---|---|---|
| Philippe Chambon, MD, Ph.D. | Managing Director |
Founding member of New Leaf (2005); joined Sprout in 1995. Age 55. Board member for multiple pharmaceutical and tech ...
|
Organizations (25)
Relationships (3)
helped found New Leaf in 2005... Managing Director
Philippe joined Sprout in 1995
provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds
Key Quotes (3)
"NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-II, and provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds."Source
HOUSE_OVERSIGHT_024022.jpg
Quote #1
"The team of six senior partners, five of whom have worked together continuously for over a decade, stands out in the industry for its depth of accomplishments..."Source
HOUSE_OVERSIGHT_024022.jpg
Quote #2
"Philippe Chambon, MD, Ph.D., (55), Managing Director, helped found New Leaf in 2005."Source
HOUSE_OVERSIGHT_024022.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (3,051 characters)
II. THE TEAM
NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-II, and provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds. The team of six senior partners, five of whom have worked together continuously for over a decade, stands out in the industry for its depth of accomplishments, track record of consistent investment success, and its organizational stability. Each of the senior partners has a strong combination of significant and relevant industry operating experience and venture capital investment experience from one or more of the Fund's targeted sectors. The New Leaf team is further strengthened by a group of experienced investment professionals who add highly relevant scientific backgrounds and investment experience.
The following timeline shows the history and progression of the New Leaf team:
History and Progression of New Leaf Team
[Timeline Graphic Header: Donaldson, Lufkin & Jenrette ("DLJ") | Credit Suisse First Boston ("CSFB") | Independent (New Leaf Ventures)]
[Timeline Data Points:]
1993: Sprout Growth II $204 million HCT: 8% Cost
1995: Sprout Capital VII $250 million HCT: 40% Cost
1997
1999: Sprout Capital VIII $750 million HCT: 21% Cost
2001: Sprout Capital IX $1.1 billion * HCT: 65% Cost
2003
2005: New Leaf Ventures I $310 million
2007: New Leaf Ventures II $450 million
2009
2011
2013
1993: Sprout Growth II $204 million HCT: 8% Cost
1995: Sprout Capital VII $250 million HCT: 40% Cost
1997
1999: Sprout Capital VIII $750 million HCT: 21% Cost
2001: Sprout Capital IX $1.1 billion * HCT: 65% Cost
2003
2005: New Leaf Ventures I $310 million
2007: New Leaf Ventures II $450 million
2009
2011
2013
[Images of 7 individuals]
SENIOR TEAM
Philippe Chambon, MD, Ph.D., (55), Managing Director, helped found New Leaf in 2005. Philippe joined Sprout in 1995 and since that time has been an active investor in all three sectors of interest for NLV-III. His investments have spanned all stages including six start ups and several later stage growth equity investments and one buy-out. Philippe is currently focused on New Leaf's Information Convergence sector and late stage biopharmaceutical investments. Philippe is currently on the boards of directors of Treato, Truveris, Karos Pharmaceuticals, Principia BioPharma and VaxInnate. He was previously on the boards of NxStage Medical (NASDAQ: NXTM), Auxilium (NASDAQ: AUXL), ePocrates (NASDAQ: EPOC, acquired by athenahealth), Nuvelo (NASDAQ: NUVO), Sapient Health Network (acquired by WebMD), Spotfire (acquired by Tibco Software), and Combichem (acquired by DuPont). He also led our investment in, and was a board observer at, Audax Health (acquired by UnitedHealth/Optum). Immediately prior to joining Sprout, Philippe was a Manager in the healthcare practice of the Boston Consulting Group. In that capacity, he managed strategy and business re-engineering assignments with clients in the pharmaceutical, biotech and insurance industry. Previously, Philippe was an executive with Sandoz Pharmaceutical for seven years, where he built and led an organization responsible for late stage clinical project management, portfolio management, and pre-marketing and pharmacoeconomics activities. He conducted graduate research in
11
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024022
CONTROL NUMBER 257 - CONFIDENTIAL
HOUSE_OVERSIGHT_024022
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document